CYP56 (Dit2p) in Candida albicans : Characterization and Investigation of Its Role in Growth and Antifungal Drug Susceptibility

Antimicrobial Agents and Chemotherapy
2008.0

Abstract

The complete DNA sequence of Candida albicans DIT2, encoding cytochrome P450 family 56 (CYP56), was obtained, and heterologous expression was achieved in Escherichia coli, where CYP56 was targeted to the membrane fraction. In reconstituted assays with the purified enzyme, CYP56 was shown to catalyze the conversion of N-formyl tyrosine into N,N'-bisformyl dityrosine, a reaction that was dependent on cytochrome P450 reductase, NADPH, and oxygen, yielding a turnover of 21.6 min(-1) and a k(s) of 26 microM. The Hill number was calculated as 1.6, indicating that two molecules of the substrate could bind to the protein. Azole antifungals could bind to the heme of CYP56 as a sixth ligand with high affinity. Both chromosomal alleles of CYP56 were disrupted using the SAT1 flipper technique, and CYP56 was found to be nonessential for cell viability under the culture conditions investigated. Susceptibility to azole drugs that bind to cytochromes P450 was tested, and the mutant showed unaltered susceptibility. However, the mutant showed increased susceptibility to the echinocandin drug caspofungin, suggesting an alteration in 1,3-glucan synthase and/or cell wall structure mediated by the presence of dityrosine. Phenotypically, the wild-type and mutant strains were morphologically similar when cultured in rich yeast extract-peptone-dextrose medium. However in minimal medium, the cyp56Delta mutant strain exhibited hyphal growth, in contrast to the wild-type strain, which grew solely in the yeast form. Furthermore, CYP56 was essential for chlamydospore formation.

Knowledge Graph

Similar Paper

CYP56 (Dit2p) in Candida albicans : Characterization and Investigation of Its Role in Growth and Antifungal Drug Susceptibility
Antimicrobial Agents and Chemotherapy 2008.0
Differential Azole Antifungal Efficacies Contrasted Using a Saccharomyces cerevisiae Strain Humanized for Sterol 14α-Demethylase at the Homologous Locus
Antimicrobial Agents and Chemotherapy 2008.0
A Clinical Isolate of Candida albicans with Mutations in ERG11 (Encoding Sterol 14α-Demethylase) and ERG5 (Encoding C22 Desaturase) Is Cross Resistant to Azoles and Amphotericin B
Antimicrobial Agents and Chemotherapy 2010.0
A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations
Antimicrobial Agents and Chemotherapy 2007.0
Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (Sterol 14α-Demethylase) Doxycycline-Regulated Mutant and Screening of the Azole Sensitivity of Aspergillus fumigatus Isoenzymes CYP51A and CYP51B
Antimicrobial Agents and Chemotherapy 2010.0
Genetic Dissection of Azole Resistance Mechanisms in Candida albicans and Their Validation in a Mouse Model of Disseminated Infection
Antimicrobial Agents and Chemotherapy 2010.0
Expression, Purification, and Characterization of Aspergillus fumigatus Sterol 14-α Demethylase (CYP51) Isoenzymes A and B
Antimicrobial Agents and Chemotherapy 2010.0
Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus
Antimicrobial Agents and Chemotherapy 2008.0
ACandida albicansPetite Mutant Strain with Uncoupled Oxidative Phosphorylation OverexpressesMDR1and Has Diminished Susceptibility to Fluconazole and Voriconazole
Antimicrobial Agents and Chemotherapy 2007.0
Optimised expression and spectral analysis of the target enzyme CYP51 from Penicillium digitatum with possible new DMI fungicides
Pest Management Science 2010.0